Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0805
    +0.0012 (+0.11%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2640
    +0.0018 (+0.14%)
     
  • USD/JPY

    151.2080
    -0.1640 (-0.11%)
     
  • Bitcoin USD

    70,222.53
    -562.19 (-0.79%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study

BioNTech SE BNTX announced that it has dosed the first patient in a phase II study on BNT122 (RO7198457), its individualized mRNA cancer vaccine candidate, for colorectal cancer.

The open-label study will investigate the efficacy of BNT122 in approximately 200 high-risk colorectal cancer patients after surgical resection of their tumors and completion of adjuvant chemotherapy. The study is underway in the United States, Germany, Spain and Belgium.

Per the company, the current standard of care for the given indication is to see whether tumors recur following removal of the primary tumor and adjuvant chemotherapy. The study will evaluate BNT122 as a single agent versus standard of care watchful waiting in this high-risk patient population.

The primary endpoint of the study is to evaluate the disease-free survival, while secondary objectives include relapse-free survival, ovserall survival and safety.

Shares of BioNTech have skyrocketed 212.6% so far this year against the industry’s decline of 7.5%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

BioNTech is jointly developing BNT122 with Genentech, a subsidiary of Swiss pharma giant Roche RHHBY.

The current phase II study was based on data from a phase Ia/Ib basket study that evaluated BNT122 as a single agent and in combination with Roche’s anti-PD-L1 antibody, Tecentriq (atezolizumab), in patients with solid tumors.

Apart from BNT122, BioNTech’s pipeline boasts of several candidates, such as BNT111, the company’s mRNA-based FixVac cancer vaccine program, and BNT113, BNT211 and BNT311, to name a few which are in early- to mid-stage studies for addressing various cancer indications.

We remind investors that BioNTech has had tremendous success with its mRNA-based COVID-19 vaccine, Comirnaty, which has been developed in partnership with Pfizer PFE. The vaccine is approved for emergency use in several countries and millions of doses have already been supplied across the globe.

Another key player in the mRNA-space is Moderna, Inc. MRNA, which has developed the popular COVID-19 vaccine, mRNA-1273. The company has several mRNA-based vaccine candidates targeting multiple diseases.

Zacks Rank

BioNTech currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Roche Holding AG (RHHBY) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Moderna, Inc. (MRNA) : Free Stock Analysis Report

BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement